
Jilin Aodong
The predecessor of Jilin Aodong Pharmaceutical Group Co., Ltd. was the state-owned Yanbian Dunhua Deer Farm established in 1957. Aodong Pharmaceutical Factory was established in 1981. In March 1993, it was restructured into Jilin Aodong Pharmaceutical Group Co., Ltd. with the approval of the Provincial Reform Commission. The company was listed on the Shenzhen Stock Exchange on October 28, 1996. The company currently holds 7 professional pharmaceutical subsidiaries engaged in modern Chinese medicine, biochemical medicine and phytochemical medicine, 1 pharmaceutical sales subsidiary, 2 pharmaceutical supporting subsidiaries, and shares in Guangfa Securities and Tadong Mining. It has planting and breeding bases. Established an industrial chain business model of “company + standardization base + franchised farmers” and gradually developed into a holding group integrating the pharmaceutical, securities, mining, and highway construction industries with “resource sharing, scientific management, and sustainable development” the company.
The company’s registered address is No. 2158, Aodong Street, Dunhua City, Jilin Province, with a total share capital of 573,357,700 shares. The legal representative is Li Xiulin.
As of the end of 2009, the company’s total assets were 7162.21 million yuan, net assets were 6.5603 million yuan, and the debt-to-asset ratio was 8.40%. In 2009, it achieved sales revenue of RMB 1.02552 million, total profit of RMB 1.413 million, and net profit of RMB 1.36649 million.
The company was recognized as a national technology center by the State Economic and Trade Commission in 1998, and has become the main technical support for enterprise technological progress and technological innovation. On December 11, 2001, the Ministry of Personnel approved the establishment of a post-doctoral workstation. During the “Tenth Five-Year Plan” period, the Jilin Aodong National Technology Center will be built into a new technology research and development center, a production-university-research cooperation exchange center, and a technology decision-making consulting center; in 2002, the company Approved by the Ministry of Agriculture and other nine ministries and commissions as a national key leading enterprise in agricultural industrialization; in September 2003, it was rated as “Excellent High-tech Enterprise in the Torch Program” by the Ministry of Science and Technology; in January 2002, it was rated as a model enterprise for the modern technology industry base of Chinese medicine ; In April 2007, he won the National May 1st Labor Certificate, and was once again rated as a key leading enterprise in agricultural industrialization by the Ministry of Agriculture and other nine ministries and commissions; in January 2008, he was rated as a Jilin Province Enterprise Informatization Demonstration Unit, and won Jilin Province A for many consecutive years Class tax-paying company, AAA bank credit rating, contract-abiding and trustworthy unit and other honors; in December 2009, it was awarded the 16th national first-class enterprise management modernization innovation achievement.
After decades of development, the company has formed a unique brand advantage. The “Aodongjitu” trademark was recognized as well-known protection by the State Administration for Industry and Commerce in 1999, and has become “China’s 500 Most Valuable Brands” for six consecutive years. The company’s leading products such as “Anshen Bu Nao Liquid”, “Xuefu Zhuyu Oral Liquid”, “Li Nao Xin Capsules”, “Xin Nao Shu Tong Capsules”, etc., have maintained the titles of Provincial Excellent, Ministry Excellent and Chinese Famous Brand Products for many years. “Cattle Spleen Extract Injection”, “Ribonucleic Acid for Injection Ⅱ”, “Lutai Granules”, “Shaofu Zhuyu Granules”, “Yangxueyin Oral Liquid”, “Yuxintong Capsules”, “Xiaoer Chaigui” “Oral Liquid” and other products have also been well received by the market for their stable quality and definite curative effect. Sales have increased year by year, laying a solid foundation for the company’s sustainable development.
The company will continue to thoroughly implement the policy of “strengthening production fine management, deepening marketing system reform, adjusting product research and development direction, advancing information network construction, improving business objective assessment, and enhancing the overall strength of the enterprise”, creating greater value for shareholders and taking into account consumption The interests of stakeholders, employees, creditors, suppliers, etc., contribute to the development of social economy.